Biologics

Aziyo Biologics is in talks to divest its orthopedic business, the company said Aug. 14.

Here are five developments in orthopedic regenerative medicine since July 11.

Orthopedic surgeon Ken Zaslav, MD, performed the first commercial case with CartiHeal's Agili-C in the U.S., the medtech company said July 26.

The CDC and FDA are investigating an outbreak of tuberculosis linked to recently recalled viable bone matrix material.

Ronald Hillock, MD, an adult joint reconstruction surgeon and musculoskeletal oncologist at Nevada Orthopedic & Spine Center in Las Vegas, connected with Becker's to answer, "Are orthobiologics overhyped?"

Gurtej Singh, MD, a physical medicine and rehabilitation physician, connected with Becker's to answer, "Are orthobiologics overhyped?"

Aziyo Biologics is recalling its viable bone matrix products after two patients were infected with Mycobacterium tuberculosis following surgeries, the orthobiologics company said July 13.

The first four surgeries using the EnFix RC fiber implant for rotator cuff repair were completed at Rush Oak Brook (Ill.) Surgery Center.

The Biden administration launched a program under the Advanced Research Projects Agency for Health focused on orthopedic tissue regeneration.

Here are five developments in orthobiologics to know since April 1: